Researchers say drug improved survival among COVID-19 patients in 'major breakthrough'


A free daily digest of the biggest news stories of the day - and the best features from our website
Thank you for signing up to TheWeek. You will receive a verification email shortly.
There was a problem. Please refresh the page and try again.
An inexpensive drug looks to be able to improve survival odds for COVID-19 patients with "severe respiratory complications," according to a new study.
Researchers on Tuesday announced the results of a study in which 2,104 patients received dexamethasone, a steroid, and 4,321 patients received usual care, The Associated Press reports. The drug reduced deaths by one-third for patients who were on ventilators and one-fifth for patients who were receiving oxygen, they said.
However, the study didn't show a benefit to patients "who did not require respiratory support," according to the announcement.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"This is an extremely welcome result," University of Oxford's Peter Horby, one of the chief investigators on the study, said in a statement. "The survival benefit is clear and large in those patients who are sick enough to require oxygen treatment, so dexamethasone should now become standard of care in these patients. Dexamethasone is inexpensive, on the shelf, and can be used immediately to save lives worldwide."
Horby also described dexamethasone, which BBC News reports is "already used to reduce inflammation in a range of other conditions," as the "first drug to be shown to improve survival in COVID-19" and told Reuters this is a "major breakthrough." Still, Axios notes the results of this trial "have not been peer-reviewed, or published formally at all." The researchers said the details will be published "as soon as possible."
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
Sign up to our 10 Things You Need to Know Today newsletter
A free daily digest of the biggest news stories of the day - and the best features from our website
Brendan is a staff writer at The Week. A graduate of Hofstra University with a degree in journalism, he also writes about horror films for Bloody Disgusting and has previously contributed to The Cheat Sheet, Heavy, WhatCulture, and more. He lives in New York City surrounded by Star Wars posters.
-
Ratings over democracy
Cartoons
By The Week Staff Published
-
Consumption rooms: a legal place for illegal drugs?
Talking Point Scotland approves UK's first trial facility where users can take drugs under medical supervision
By Richard Windsor, The Week UK Published
-
'Biden must be embarrassed he didn't think of this first'
Instant opinion Opinion, comment and editorials of the day
By Harold Maass Published
-
FDA to re-evaluate effectiveness of common nasal congestion ingredient
Speed Read
By Justin Klawans Published
-
A flesh-eating bacteria is growing in numbers due to climate change
Speed Read
By Devika Rao Published
-
CDC recommends new RSV vaccine for infants under 8 months
Speed Read
By Devika Rao Published
-
U.S. health agency advises easing federal marijuana restrictions
Speed Read
By Peter Weber Published
-
Medicare drug price negotiations start with 1st 10 drugs, pharmaceutical industry lawsuits
Speed Read
By Peter Weber Published
-
Air pollution may be increasing antibiotic resistance, new research suggests
Speed Read
By Devika Rao Published
-
Tick bites could cause an allergy to red meat, CDC says
Speed Read
By Devika Rao Published
-
The danger of drinking too much water
Speed Read
By Devika Rao Published